FDA OKs Pembro Plus Lenvatinib For First-Line in Kidney Cancer FDA OKs Pembro Plus Lenvatinib For First-Line in Kidney Cancer

Results from the phase 3 CLEAR trial showed significant survival benefits with the combination when compared with lenvatinib-everolimus or sunitinib monotherapy.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news